CASE REPORT

Open Access

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Teppei Sugano¹, Masahiro Seike^{1*}, Yoko Funasaka², Mai Yoshida², Ryoko Takayama², Ken Okamura¹, Asuka Nakanishi¹, Toru Tanaka¹, Susumu Takeuchi¹, Rintaro Noro¹, Yuji Minegishi¹, Kaoru Kubota¹, Hidehisa Saeki² and Akihiko Gemma¹

Abstract

Background: Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adverse events, involving the lung, liver, gastrointestinal, endocrine system, and skin. Intralymphatic histiocytosis (ILH) is a rare, chronic cutaneous disorder with a reactive inflammatory component, which often occurs in patients with rheumatoid arthritis.

Case presentation: We present a 67-year-old man with lung adenocarcinoma who developed ILH associated with pembrolizumab treatment. He was treated with palliative thoracic radiotherapy for superior vena cava syndrome. Subsequently, he received four cycles of pembrolizumab. Approximately 2.5 months after the initiation of pembrolizumab, he developed erythema on the trunk of his body. Based on findings of skin biopsies, he was diagnosed with pembrolizumab-induced ILH. Moreover, the upregulation of tumor necrosis factor- α was observed during pembrolizumab therapy.

Conclusions: This is the first report of ILH induced by pembrolizumab in a patient with lung adenocarcinoma.

Keywords: Lung adenocarcinoma, Pembrolizumab, Intralymphatic histiocytosis

Background

Recently, immune checkpoint inhibitors (ICIs) have shown promising results in clinical trials and are recognized as the standard treatment for advanced non-small-cell lung cancer (NSCLC) [1, 2]. Pembrolizumab, an anti-programmed death (PD-1) antibody, has shown favorable antitumor efficacy in NSCLC patients [1, 2]. Of note, patients with high levels of programmed death ligand 1 (PD-L1) expression (tumor proportion score [TPS] $\geq 50\%$) treated with pembrolizumab had significant survival benefit in untreated metastatic NSCLC [2].

ICIs can induce unique adverse events including pneumonitis, colitis, thyroiditis, and dermatitis, which collectively are termed immune-related adverse events

(ir-AEs) [3]. The most frequent cutaneous ir-AEs are maculopapular eruption, lichenoid reactions, pruritus, and vitiligo [4, 5]. Intralymphatic histiocytosis (ILH) is characterized by the presence of dilated lymphatic vessels containing aggregates of mononuclear histiocytes (macrophages) within their lumina in the dermis. It was previously reported that tumor necrosis factor α (TNF- α) is associated with the pathogenesis of ILH. Here, we report the first case of ILH associated with pembrolizumab treatment and the upregulation of TNF- α in a patient with lung adenocarcinoma.

Case presentation

A 67-year-old man who was a current smoker presented with an edematous right arm and face in our hospital. A chest computed tomography (CT) scan revealed a tumor of approximately 40 mm in diameter in the right upper lobe, with right axial and mediastinal lymph node

* Correspondence: mseike@nms.ac.jp

¹Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan

Full list of author information is available at the end of the article

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

metastases, and pleural effusion (Fig. 1a and b). According to the findings of a transbronchial lung biopsy and systemic survey, he was diagnosed with adenocarcinoma corresponding to clinical T4N3M1c (stage IVB: 8th edition of UICC TNM staging). An epidermal growth factor receptor mutation and rearranged anaplastic lymphoma kinase genes were not detected. His tumor had invaded the superior vena cava (SVC), leading to the swelling of his right arm and face, suggesting SVC syndrome. He was treated with palliative radiotherapy consisting of a total dose of 30 Gy for SVC syndrome. After irradiation, the size of the tumor in the right upper lobe was slightly decreased (Fig. 1c and d). Immunohistochemistry using the 22C-3 antibody revealed the high expression of PD-L1 and a TPS of 75%. He did not have a personal or family history of any autoimmune conditions and autoimmune related antibodies such as anti Jo-1 antibody, anti-thyroid peroxidase antibody, anti-thyroid stimulating hormone antibody, free T3, free T4, rheumatoid factor (RF), anti-acetylcholine receptor antibody, antinuclear antibody and anti-glutamic acid decarboxylase antibody did not show abnormal findings. Subsequently, pembrolizumab (200 mg/body, every 3 weeks) was initiated as the first-line therapy. Approximately 2.5 months after treatment with pembrolizumab, he presented with an asymptomatic, poorly demarcated 1–3 cm erythematous plaque over the right trunk of his body, which gradually developed in size

(Fig. 2a and b). He had no symptoms and his blood examination test results showed no remarkable changes. Therefore, pembrolizumab therapy was continued. Histopathologic examination from a skin biopsy showed ectatic dermal lymphatics with intraluminal aggregations of histiocytes (Fig. 2c), which were positive for CD68 and lymphatic vessels that were positive for podoplanin (D2–40) (Fig. 2d and e). We ultimately diagnosed him as ILH based on the clinical and histopathological findings. RF and anti-cyclic citrullinated peptide (CCP) antibody were checked after the appearance of erythematous plaques; however, they were negative. Laboratory results revealed that TNF- α levels were increased after 2 months of pembrolizumab treatment (Fig. 3). After 4 cycles of pembrolizumab treatment, the size of the tumor in right upper lobe had decreased. However, the tumor in the axial lymph node progressed (Fig. 4a and b) and his right arm swelling worsened. Therefore, the treatment was changed to cisplatin (75 mg/m²) and pemetrexed (500 mg/m²) as second-line therapy. After 2 cycles of chemotherapy, he maintained a partial response without any severe adverse events and ILH was gradually resolved with topical steroid therapy.

Discussion

Cutaneous ir-AEs present with a wide range of clinical appearances. Hwang et al. [6] reported that 49% of

Fig. 1 Chest computed tomography analysis determines the baseline before pembrolizumab therapy. A tumor approximately 43 mm in diameter in the right upper lobe, right axial and mediastinal lymph node metastases, and pleural effusion were observed (a, b). After palliative radiotherapy, the size of the right axial lymph node metastasis was decreased (c, d)

Fig. 2 Clinical appearance. A reddish-brown plaque with edema was present on the right side of the trunk of his body (a, b). Histopathological findings of the patient's skin biopsy specimens (magnification, 200x). Inflammatory cells, including lymphocytes, plasma cells and macrophages, were present in the dilated vessels (c). Immunostaining revealed aggregates of CD68 positive histiocytes (d) and endothelial cells lining the vessels were positive for D2-40 (e)

melanoma patients undergoing anti-PD-1 therapy developed dermatologic toxicity. Curry et al. categorized four types of cutaneous ir-AEs as inflammatory, immunobullous, alteration of epidermal keratinocytes, and alteration of epidermal melanocytes [7]. Among cutaneous ir-AEs, skin rash (inflammatory group), pruritus (inflammatory group) and vitiligo (alteration of epidermal melanocytes group) are frequently observed.

ILH is a rare, dermatologic disorder that represents the accumulation of histiocytes within the ectatic lymphatics. ILH was first reported in 1994 [8] as dilated dermal vessels containing collections of mononuclear histiocytes (macrophages) within their lumina. In 1999, Rieger et al. [9] reported two similar patients, one of which had a history of rheumatoid arthritis (RA). In 2005, Okazaki et al. [10] demonstrated the lymphatic nature of the enlarged vessels by assessing the expression of a lymphatic endothelial marker, D2-40. The concept

of ILH was established after these findings were reported. ILH is also defined by the accumulation of CD68 positive histiocytes within dilated lymphatic vessels. Barba et al. [11] summarized 59 ILH cases and 23 cases associated with RA. Clinically, most lesions of ILH develop as isolated asymmetrical erythematous plaques with or without a livedo-like pattern, papules, vesicles, or nodules on the extremities. The cause of ILH remains unknown but might be related to intrinsic lung cancer biology or tumor progression. Barba et al. [11] reported six ILH patients with malignant tumors of the breast, colon, as well as melanoma. Secondary ILH often occurs with RA; therefore, the pathogenesis of this disorder might be associated with chronic inflammation. Regarding its role in RA, chronic inflammation might cause lymphostasis leading to the poor clearance of antigen and localized immune dysfunction, subsequently promoting the stimulation and proliferation of histiocytosis

in the lymphatic vessels [12]. In addition, TNF- α , a pro-inflammatory cytokine and a critical mediator of the inflammation in RA [13], plays a crucial role in the pathogenesis of ILH. A previous study [14] reported the effectiveness of infliximab, an anti-TNF- α antibody, against ILH [15]. Treatment algorithms for managing ir-AEs recommend the use of immune suppressants such as corticosteroids and in more severe cases, the use of infliximab [16]. It was reported that a certain proportion of patients treated with ICIs experienced severe colitis and that infliximab improved colitis [17]. In the current case, TNF- α levels were elevated after pembrolizumab treatment. Therefore, TNF- α might play an important role in the induction of ILH in this case.

He received palliative radiotherapy before pembrolizumab treatment. Recently, radiation therapy was

shown to activate immune responses. Abscopal effects were used to describe the phenomenon of tumor regression in untreated metastatic lesions after local treatment, such as radiotherapy [18]. The potential mechanism of abscopal effects might involve the triggering of increased tumor antigen release and presentation to T-cells by irradiation of the lesion, which subsequently enhances immunological responses. Therefore, his risk for ILH might be increased by the radiation treatment. It was reported that the abscopal effect synergized with the presence of immunotherapy [19]. In the PACIFIC study, ir-AEs of any grade were 24.2% in the PD-L1 inhibitor (durvalumab) group and 8.1% in the placebo group [20]. Based on these findings, a synergic effect with radiation therapy and pembrolizumab might induce ILH as well as pembrolizumab alone.

Fig. 4 After 4 cycles of pembrolizumab administration, the size of the right axial lymph node metastasis was increased (a, b)

Conclusion

In summary, this is the first case of secondary ILH induced by pembrolizumab therapy and the first report to the best of our knowledge to confirm the upregulation of TNF- α . Further studies are needed to clarify the mechanisms of Ir-AEs following immunotherapy.

Abbreviations

ICIs: immune checkpoint inhibitors; ILH: Intralymphatic histiocytosis; NSCLC: non-small-cell lung cancer; PD-1: anti-programmed death; PD-L1: programmed death ligand 1; TNF- α : tumor necrosis factor α

Acknowledgements

We thank the patient and his family for letting us present his case in this report.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TS, KO, AH and TT treated the patient. YF analyzed the histological sections. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Written informed consent was obtained from the patient for the analysis of the samples and the tissues.

Consent for publication

Consent for publication was obtained from the patient. A copy of the written consent is available for review.

Competing interests

Masahiro Seike, Kaoru Kubota, and Akihiko Gemma have received honorarium from Merck Sharp & Dohme. The authors report no other conflicts of interest in this work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. ²Department of Dermatology, Nippon Medical School, Tokyo, Japan.

Received: 11 October 2018 Accepted: 12 February 2019

Published online: 27 February 2019

References

- Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016;387(10027):1540–50.
- Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csomos T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*. 2016;375(19):1823–33.
- Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer*. 2016;54:139–48.
- Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. *JAMA Dermatol*. 2015;151(11):1206–12.

- Uenami T, Hosono Y, Ishijima M, Kanazu M, Akazawa Y, Yano Y, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report. *Lung Cancer*. 2017;109:42–4.
- Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. *J Am Acad Dermatol*. 2016;74(3):455–61 e1.
- Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. *J Cutan Pathol*. 2017;44(2):158–76.
- O'Grady JT, Shahidullah H, Doherty VR, al-Nafussi A. Intravascular histiocytosis. *Histopathology*. 1994;24(3):265–8.
- Rieger E, Soyer HP, Leboit PE, Metze D, Slovak R, Kerl H. Reactive angioendotheliomatosis or intravascular histiocytosis? An immunohistochemical and ultrastructural study in two cases of intravascular histiocytic cell proliferation. *Br J Dermatol*. 1999;140(3):497–504.
- Okazaki A, Asada H, Niizeki H, Nonomura A, Miyagawa S. Intravascular histiocytosis associated with rheumatoid arthritis: report of a case with lymphatic endothelial proliferation. *Br J Dermatol*. 2005;152(6):1385–7.
- Barba E, Colato C, Girolomoni G. Intralymphatic Histiocytosis: a case report and review of literature. *J Cutan Pathol*. 2015;42(9):593–9.
- Requena E, El-Shabrawi-Caelen L, Walsh SN, Segura S, Ziemer M, Hurt MA, et al. Intralymphatic histiocytosis. A clinicopathologic study of 16 cases. *Am J Dermatopathol*. 2009;31(2):140–51.
- Perdrieger A. Infliximab in the treatment of rheumatoid arthritis. *Biologics*. 2009;3:183–91.
- Sakaguchi M, Nagai H, Tsuji G, Morinobu A, Kumagai S, Nishigori C. Effectiveness of infliximab for intralymphatic histiocytosis with rheumatoid arthritis. *Arch Dermatol*. 2011;147(1):131–3.
- Bakr F, Webber N, Fassihi H, Swale V, Lewis F, Ryntina E, et al. Primary and secondary intralymphatic histiocytosis. *J Am Acad Dermatol*. 2014;70(5):927–33.
- Brahmer JR, Lacchetti C, Thompson JA. Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. *J Oncol Pract*. 2018;14(4):247–9.
- Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. *Clin Gastroenterol Hepatol*. 2017;15(4):e80–e1.
- Mole RH. Whole body irradiation; radiobiology or medicine? *Br J Radiol*. 1953;26(305):234–41.
- Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. *Oncoimmunology*. 2014;3:e28780.
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. *N Engl J Med*. 2017;377(20):1919–29.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions